Amarin Corporation plc (AMRN)

Market Cap	315.17M +47.5%
Revenue (ttm)	216.76M +1.2%
Net Income	-33.61M
EPS	-1.61
Shares Out	20.97M
PE Ratio	n/a
Forward PE	19.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,589
Open	14.95
Previous Close	14.95
Day's Range	14.81 - 15.29
52-Week Range	9.98 - 20.90
Beta	0.82
Analysts	Strong Sell
Price Target	12.00 (-20.16%)
Earnings Date	Apr 29, 2026

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaborat...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Apr 1, 1993
• Employees: 80
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRN
• Website: https://www.amarincorp.com

Financial Performance

In 2025, Amarin Corporation's revenue was $213.65 million, a decrease of -6.55% compared to the previous year's $228.61 million. Losses were -$38.80 million, -52.79% less than in 2024.

Analyst Summary

According to one analyst, the rating for AMRN stock is "Strong Sell" and the 12-month stock price target is $12.0.

Price Target

$12.0

(-20.16% downside)

Analyst Consensus: Strong Sell